Skip to main content

Table 1 Clinico-pathological data of the study cohort

From: HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Characteristic

All cases, number (%)

Centrally evaluated HER2-

positive cases, number (%)

Centrally evaluated HER2-

negative cases, number (%)

Samples, number

217

158

59

Local HER2 status (IH/ISH)

   

   positive

217 (100)

158 (100)

59 (100)

   negative

0 (0)

0 (0)

0 (0)

Central HER2 status (IH/SISH)

   

   Positive

158 (72.8)

158 (100)

0 (0)

   Negative

59 (27.2)

0 (0)

59 (100)

HER2 protein expression (central IH)

   

   3+

144 (66.4)

144 (91.1)

0 (0)

   2+

20 (9.2)

8 (5.1)

12 (20.3)

   0/1+

48 (22.1)

2 (1.3)

46 (78.0)

   missing

5 (2.3)

4 (2.5)

1 (1.7)

HER2 gene amplification (central SISH)

   

   SISH positive (>2.2)

109 (50.2)

109 (69.0)

0 (0)

   SISH negative (<1.8)

49 (22.6)

10 (6.3)

39 (66.1)

   SISH equivocal (1.8-2.2)

8 (3.7)

6 (3.8)

2 (3.4)

   missing

51 (23.5)

33 (20.9)

18 (30.5)

HER2 mRNA expression (central qPCR)

   

   Positive (>19.5)

141 (65.0)

137 (86.7)

4 (6.8)

   Negative (≤19.5)

76 (35.0)

21 (13.3)

55 (93.2)

ER/PR Status (local IH)

   

   ER+ and/or PR+

125 (57.6)

84 (53.2)

41 (69.5)

   ER-/PR-

92 (42.4)

74 (46.8)

18 (30.5)

ESR1 mRNA expression (central qPCR)

   

   Positive (>13.8)

109 (50.2)

70 (44.3)

39 (66.1)

   Negative (≤13.8)

108 (49.8)

88 (55.7)

20 (33.9)

Tumor grade

   

   G1 to G2

114 (55.1)

78 (49.4)

36 (61.0)

   G3

93 (44.9)

72 (45.6)

21 (35.6)

   Missing

10 (4.6)

8 (5.1)

2 (3.4)

Clinical tumor stage

   

   cT1 to cT2

155 (71.4)

110 (69.6)

45 (76.3)

   cT3 to cT4

62 (28.6)

48 (30.4)

14 (23.7)

Clinical nodal status

   

   cN0

83 (38.2)

61 (38.6)

22 (37.3)

   cN+

134 (61.8)

97 (61.4)

37 (62.7)

Pathological response

   

   No pCR

131 (60.4)

84 (53.2)

47 (79.7)

   pCR (ypT0/is ypN0)

86 (39.6)

74 (46.8)

12 (20.3)

Age group

   

   ≤ 50 years

109 (50.2)

84 (53.2)

25 (42.4)

   > 50 years

108 (49.8)

74 (46.8)

34 (57.6)

Tumor type

   

   Ductal/other

207 (95.4)

156 (98.7)

51 (86.4)

   Lobular

10 (4.6)

2 (1.3)

8 (13.6)

  1. HER2, human epidermal growth factor receptor 2; SISH, silver in situ hybridization; IH: immunohistochemistry; ISH: in situ hybridization; qPCR, quantitative polymerase chain reaction; ypT: tumor stage after neoadjuvant therapy; ypN: nodal status after neoadjuvant therapy.